Medical device maker Medtronic on Thursday announced the U.S. commercial launch of its latest device, the MiniMed 630G Insulin Pump System. Medtronic is headquartered in Dublin, while its diabetes division is located in Northridge. This new system — which pairs an insulin pump with a sensor to monitor and deliver insulin to diabetics — has many of the same features as its predecessor the MiniMed 530G system but also has a new insulin pump and more streamlined design. Some of its other features include a high-definition full-color screen, increased customization capabilities as well as more user-friendly menus. “This latest innovation demonstrates Medtronic’s vision to transform diabetes care to enable greater freedom and better health through a commitment to continually improving both outcomes and user experience,” Alejandro Galindo, president of the Intensive Insulin Management business at Medtronic, said in a statement. Medtronic closed up 58 cents, or less than 1 percent, to $87.80 on the New York Stock Exchange.
